Compressed-tablet manufacture with ketoconazole veterinary-grade API begins at the pH-solubility boundary. The substance is a weak dibasic imidazole derivative with molecular weight 531.43 g/mol and pKa values near 2.9 and 6.5. Its aqueous solubility remains below 0.1 mg/mL at neutral pH, while protonation under gastric-acid conditions in the range of pH 1.0–3.0 raises apparent solubility sufficiently for dissolution. Tablet formulations that omit an acidified microenvironment can pass disintegration testing but still fail dissolution because the unprotonated free base precipitates at the tablet surface. Air-jet milling is typically targeted to a D90 in the 10–30 µm band by laser diffraction; a D90 above 150 µm is a known cause of slowed release in 0.1 N hydrochloric acid media. Fumaric acid at 5–15 wt% is incorporated intragranularly as a non-hygroscopic acidulant, with crospovidone at 3–5 wt% as disintegrant and microcrystalline cellulose at 20–40 wt% as compressible filler. On high-shear granulators with working volumes from 25 L to 600 L, purified water is sprayed at 2–5% additions per minute until a loss-on-drying endpoint of 1.0–2.5% is reached. Magnesium stearate is then added at 0.25–1.0 wt% with a 3–5 minute final blend. Lubrication longer than 10 minutes is avoided because the hydrophobic film suppresses the acidified dissolution front. Tablet hardness is maintained between 60 N and 120 N for 8–13 mm round cores, with friability below 1.0% under USP <1216>. Content uniformity follows USP <905> with an acceptance value of no more than 15.0. Dissolution is evaluated in 900 mL of 0.1 N hydrochloric acid using USP <711> Apparatus 2 at 50–75 rpm and 37°C with product-specific Q criteria. Veterinary use in dogs for Malassezia dermatitis, dermatophytosis, or systemic mycoses commonly follows published oral dose references of 5–10 mg/kg every 12–24 h administered with food. because ketoconazole exposure can inhibit CYP3A-dependent clearance, the clinical risk from co-administered cyclosporine, ivermectin, or macrolides is managed outside the compression suite, while the tablet unit operation remains focused on particle size, acidulant distribution, and lubricant over-blend avoidance.

The tablet cores are film-coated with an aqueous HPMC system containing titanium dioxide and iron oxide. Pan inlet air is held at 60–65°C while the product-bed temperature is kept below 40°C to reduce water uptake and prevent softening of the fumaric acid-containing core. PVC/PCTFE blister cavities are selected when storage above 60% RH is expected because the acidulant can deliquesce and create local low-pH microenvironments that alter dissolution over time. Stability protocols follow VICH GL3 with storage at 25°C/60% RH and 40°C/75% RH, with assay, dissolution, dissolution media pH, and related substances measured at 0, 3, and 6 months. Residual solvent and elemental impurity control are aligned with ICH Q3C and ICH Q3D, although the API is used under veterinary extra-label provisions such as 21 CFR 530 in the United States when no approved veterinary product is available.

What limits injectable ketoconazole sterility in pH-shifted vehicles?

Injectable dosage forms expose the main physical incompatibility of ketoconazole as a free base. Published aqueous solubility data place the substance in the practically insoluble class above pH 5.0. A 10 mg/mL strength requires either co-solvent vehicles containing polyethylene glycol 300, propylene glycol, ethanol, and benzyl alcohol, or inclusion complexes with hydroxypropyl-β-cyclodextrin. A representative investigational vehicle uses 30–40% v/v propylene glycol, 10–20% v/v ethanol, and sufficient hydrochloric acid to reach pH 3.0–3.5. This holds the API in solution during cold compounding, but the thermodynamic risk of precipitation on dilution or during refrigerated storage is high. Terminal sterilization by autoclaving at 121°C for 15 minutes is commonly unsuitable because it can alter pH and generate degradation products. Investigational sterile preparations are therefore filtered through a 0.22 µm PVDF membrane under aseptic conditions. USP <788> particulate matter limits for small-volume injectables must be verified at the end of the intended storage interval because crystal growth can appear within 7–14 days in unbuffered co-solvent systems. Endotoxin control follows USP <85> with a dose-derived limit; for a parenteral dose of 5 mg/kg in a 20 kg dog, the endotoxin exposure would be constrained by the maximum recommended human parenteral limit of 5 EU/kg/h. There is no approved veterinary parenteral ketoconazole product in the United States or European Union, and published data for this specific configuration are limited to experimental pharmacokinetic models and zoological formularies. The operational boundary is not sterility alone but injection-site pain, hemolysis, and precipitation when the vehicle contacts tissue pH above 7.0. These factors restrict injectable use to investigational protocols where the risk–benefit calculation is documented under 21 CFR part 511 or an equivalent research authorization.

For birds, ferrets, rabbits, and small exotic mammals with dose-titration requirements below 1 mg/kg or with esophageal anatomy that prevents tablet passage, an aqueous oral suspension or compounded solution is prepared from the same API. The vehicle is acidified with citric acid to a pH of 2.0–4.0 because the weakly basic ketoconazole molecule requires the protonated state for dissolution. A suspending agent combination of sodium carboxymethylcellulose at 0.5–1.0% w/v and microcrystalline cellulose/carboxymethylcellulose sodium at 1.0–2.0% w/v prevents hard caking in high-density solutions. Sorbitol at 20–30% w/v is used for taste masking, but its hygroscopic uptake above 60% relative humidity shortens beyond-use dating. Compounded preparations are nonsterile and are evaluated under USP <795> rather than a finished pharmaceutical monograph. Without preservatives such as methylparaben at 0.1% and propylparaben at 0.02%, microbial growth in citrus-flavored syrup bases can appear within 14 days. A beyond-use date of 30 days at 2–8°C is assigned only when supported by stability-indicating HPLC assay per USP <621>. Concomitant therapy with omeprazole or famotidine in avian patients is a known cause of therapeutic failure because the gastric pH rises above the protonation range and the drug remains undissolved. Repeated shaking of the suspension is required because the saturated solution can crystallize when warmed to room temperature during shipment.

Powder-in-capsule homogeneity and segregation limits

Dose-adjusted capsules for canine or feline patients are produced by direct filling rather than granulation. The jet-milled API exhibits high electrostatic charge, so a pre-blend step at 1 part ketoconazole to 10 parts lactose monohydrate is performed in a V-blender at 50–60% fill volume for 10–15 minutes. The pre-blend is then passed through a 30-mesh screen to break agglomerates and reduce content variability. Final blend testing by HPLC or near-infrared should reach a relative standard deviation below 5.0% across sampling ports in a 50 L bin blender. Capsule fill weight is calculated from the labeled dose and the bulk density of the blend, corrected for angle of repose. A powder blend with an angle of repose above 40° is considered poorly flowing and requires colloidal silicon dioxide at 0.5–1.5% w/w to maintain die feed uniformity in semi-automatic capsule machines. Dissolution of the filled capsules is measured in 0.1 N hydrochloric acid under USP <711> Apparatus 1 or 2, with sinkers for capsules that float. A frequent batch failure is not low dissolution but high dose weight variation caused by segregation of micronized API from coarse lactose. This is controlled by preparing the API as a granulated intermediate with the acidulant and binder in a high-shear granulator before capsule filling, rather than relying on simple dry dilution. Gelatin and HPMC shells are both usable, but prolonged exposure to stearyl alcohol or other lipophilic fillers is not recommended because the API partitions into the lipid phase and release slows.

When feed premix granules are stored above 25 °C in polywoven bags

Because group treatment in shelters, breeding colonies, or zoological populations requires homogeneous dosing across many animals, ketoconazole may be manufactured as a medicated premix or granulated feed additive. This route is prohibited for food-producing animals in major jurisdictions because of residue uncertainty and the absence of a maximum residue limit under EU Regulation 37/2010 and United States tolerance frameworks. The pharmaceutical granulation consists of API, lactose or corn starch as carrier, purified water or starch paste as binder, and a drying step in a fluid-bed dryer with inlet air at 50–60°C until moisture is ≤ 5.0%. Production-scale mixing in a ribbon blender requires geometric dilution from a 1% active premix to a 0.1% finished premix. Blend time is validated by sampling 10–20 locations and confirming assay uniformity with an acceptance value ≤ 15.0. The critical storage failure occurs when polywoven bags without aluminum foil liners are stored above 25°C and 60% RH: the granules absorb moisture, the carrier softens, and distribution into the final diet becomes uneven. Desiccant pouches and an overwrap moisture barrier are used below 25°C and 60% RH. Testing for aerobic microbial quality follows USP <61> and <62>, with total aerobic microbial count ≤ 10³ CFU/g and absence of Salmonella in 10 g. Particle size distribution is checked by sieve analysis through 20, 40, 80, and 120 mesh screens, with the active fraction preferentially retained in the 40–80 mesh range to prevent segregation. This route requires veterinary oversight and is limited to non-food animal populations.

Topical solution vehicles alter transepidermal delivery without thermal processing

For localized Malassezia pododermatitis or seborrheic dermatitis in dogs, ketoconazole is formulated as a topical solution, spray, or otic solution. Because systemic absorption from intact skin is not the primary target, the formulation challenge is maintaining solubility after solvent evaporation without leaving particulate residue. A hydroalcoholic vehicle containing 40–60% v/v ethanol, 10–20% v/v propylene glycol, and purified water at pH 4.0–6.0 keeps the drug in solution during manufacture and spraying. On skin, the alcohol evaporates and the drug may precipitate onto the stratum corneum. Deposition is assessed using in vitro Franz diffusion cells with excised canine abdominal skin, comparing the amount retained in the stratum corneum, epidermis, and dermis over 24 h. Such systems are nonsterile, so USP <61> and <62> microbial limits apply after packaging in high-density polyethylene spray bottles. Propellant-driven mists require aluminum can compatibility testing because ketoconazole can interact with uncoated metal surfaces at acidic pH. The solution is not an otic primary therapy when the tympanic membrane is ruptured. Stability-indicating HPLC per USP <621> should demonstrate no unknown peak above 0.5% after 3 months at 40°C/75% RH. Packaging must protect against ethanol vapor loss through low-density plastics, which would drop the solvent capacity and produce crystal growth inside the spray pump.